ES2146226T3 - Utilizacion de una composicion celular para el tratamiento de los organismos humanos o animales. - Google Patents

Utilizacion de una composicion celular para el tratamiento de los organismos humanos o animales.

Info

Publication number
ES2146226T3
ES2146226T3 ES93900251T ES93900251T ES2146226T3 ES 2146226 T3 ES2146226 T3 ES 2146226T3 ES 93900251 T ES93900251 T ES 93900251T ES 93900251 T ES93900251 T ES 93900251T ES 2146226 T3 ES2146226 T3 ES 2146226T3
Authority
ES
Spain
Prior art keywords
treatment
animal organisms
human
compositions
cellular composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93900251T
Other languages
English (en)
Inventor
Claude Roth
Lluis Mir
Philippe Kourilsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Institut Pasteur
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9418997&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2146226(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Institut Pasteur filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Application granted granted Critical
Publication of ES2146226T3 publication Critical patent/ES2146226T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

COMPOSICION DESTINADA A TRATAR LOS ORGANISMOS HUMANOS O ANIMALES COMPRENDIENDO CELULAS QUE TRANSMITEN LOS GENES QUE LES PERMITEN PRODUCIR EN VIVO UNA O VARIAS SUSTANCIAS BILOGICAMENTE ACTIVAS, DICHAS CELULAS PRESENTAN UNAS CARACTERISTICAS GENETICAS QUE LAS IMPIDEN DESARROLLARSE DURADERAMENTE EN EL ORGANISMO TRATADO Y LAS VUELVEN SUSCEPTIBLES DE SER ELIMINADAS ARTIFICIALMENTE O NATURALMENTE DEL ORGANISMO. ESTAS COMPOSICIONES PUEDEN SER EN PARTICULAR UTILIZADAS EN EL TRATAMIENTO DE TUMORES O AFECCIONES CANCEROSAS, EN CUYO CASO LAS SUBSTANCIAS UTILIZADAS SERAN LAS INTERLEUKINAS. LAS CELULAS CONTENIDAS EN ESTAS COMPOSICIONES SON AL MENOS PARCIALMENTE ALLOGENICAS O XENOGENICAS.
ES93900251T 1991-11-15 1992-11-13 Utilizacion de una composicion celular para el tratamiento de los organismos humanos o animales. Expired - Lifetime ES2146226T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9114119A FR2683725B1 (fr) 1991-11-15 1991-11-15 Composition cellulaire pour le traitement des organismes humains ou animaux.

Publications (1)

Publication Number Publication Date
ES2146226T3 true ES2146226T3 (es) 2000-08-01

Family

ID=9418997

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93900251T Expired - Lifetime ES2146226T3 (es) 1991-11-15 1992-11-13 Utilizacion de una composicion celular para el tratamiento de los organismos humanos o animales.

Country Status (13)

Country Link
US (1) US6074637A (es)
EP (1) EP0579791B1 (es)
JP (2) JPH06504450A (es)
AT (1) ATE193323T1 (es)
AU (1) AU671090B2 (es)
CA (1) CA2098720C (es)
DE (1) DE69231093T2 (es)
DK (1) DK0579791T3 (es)
ES (1) ES2146226T3 (es)
FR (1) FR2683725B1 (es)
GR (1) GR3034192T3 (es)
SG (1) SG48066A1 (es)
WO (1) WO1993010219A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5662896A (en) * 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
DE4303751C1 (de) * 1993-02-09 1994-09-08 Intracon Sarl Verfahren zur Wiederverwertung von Filterstäuben
US20050169900A1 (en) * 1993-02-17 2005-08-04 Sloan Kettering Institute For Cancer Research Allogeneic vaccine and methods to synthesize same
DE69433110T2 (de) * 1993-02-17 2004-06-03 Sloan-Kettering Institute For Cancer Research Allogenes vakzin und synthesemethode für selbiges
FR2709309B1 (fr) * 1993-08-25 1995-11-10 Centre Nat Rech Scient Compositions cellulaires, préparation et utilisations thérapeutiques.
AUPM543894A0 (en) * 1994-05-04 1994-05-26 Commonwealth Scientific And Industrial Research Organisation An adjuvant
IL132164A0 (en) * 1997-04-09 2001-03-19 Chang Lung Ji Animal model for evaluation of vaccines
US6730512B2 (en) 1997-04-09 2004-05-04 Amdl, Inc. Combination immunogene therapy
ES2218994T3 (es) * 1998-02-02 2004-11-16 The Johns Hopkins University School Of Medicine Linea celular inmunomoduladora universal que expresa citocinas y composiciones relacionadas y procedimientos de fabricacion y uso.
US20030170898A1 (en) * 2001-12-04 2003-09-11 Gundersen Martin A. Method for intracellular modifications within living cells using pulsed electric fields
TWI776276B (zh) * 2019-11-13 2022-09-01 中國醫藥大學 異種組織細胞組合物治療癌症之用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783407A (en) * 1985-09-30 1988-11-08 Merck & Co., Inc. Growth of hepatitus A virus in vero cells
US5219740A (en) * 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
EP0456640A1 (en) * 1988-12-13 1991-11-21 UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Genetically engineered endothelial cells and use thereof
CA2091346C (en) * 1990-09-14 2007-04-24 Philip Frost Methods and compositions for genetic therapy and potentiation of anti-tumor immunity
US5358866A (en) * 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
DE69231250T2 (de) * 1991-10-21 2001-03-15 Cell Genesys, Inc. Kombinierte zelluläre und immunsuppressive therapien

Also Published As

Publication number Publication date
DE69231093T2 (de) 2001-02-01
JP2004026802A (ja) 2004-01-29
WO1993010219A1 (fr) 1993-05-27
AU3163193A (en) 1993-06-15
ATE193323T1 (de) 2000-06-15
FR2683725A1 (fr) 1993-05-21
DK0579791T3 (da) 2000-10-30
EP0579791B1 (fr) 2000-05-24
AU671090B2 (en) 1996-08-15
JPH06504450A (ja) 1994-05-26
SG48066A1 (en) 1998-04-17
FR2683725B1 (fr) 1995-07-07
DE69231093D1 (de) 2000-06-29
EP0579791A1 (fr) 1994-01-26
GR3034192T3 (en) 2000-11-30
CA2098720A1 (fr) 1993-05-16
US6074637A (en) 2000-06-13
CA2098720C (fr) 2003-01-21

Similar Documents

Publication Publication Date Title
MX9203313A (es) Derivados de quinolina y sus usos para controlar el crecimiento indeseado de plantas.
ES2146226T3 (es) Utilizacion de una composicion celular para el tratamiento de los organismos humanos o animales.
ES2187785T3 (es) 3,5-difenil-1,2,4-triazoles sustituidos y su uso como queladores farmaceuticos de metales.
ES2132041T1 (es) Procesabilidad y resistencia al reteado mejoradas cuando se incorporan pigmentos silanizados en polimeros.
FI893022A0 (fi) Stabila preparat innehaollande fettloesliga aemnen och framstaellning daerav.
ECSP045407A (es) Benzazoles sustituidos y el uso del mismo como inhibidores de quinasa raf
ES2107648T3 (es) Acidos hidroxamicos substituidos con arilsulfonamido.
ES2096639T3 (es) Derivados de benzofurano, benzotiofeno, indol o indolizina, su procedimiento de preparacion, asi como las composiciones que los contienen.
AR023400A1 (es) Metodos para inducir la muerte de celulas cancerosas y la regresion de tumores
CY1111912T1 (el) Μεθοδος αναστολης της δραστηριοτητας των οστεοκλαστων
CY1105221T1 (el) Ιατρικη χρηση θυρεοειδομιμητικων ενωσεων για την θepαπευτικη αγωγη της τριχοπτωσης και φαρμακευτικες συνθεσεις
CR7877A (es) Derivados de 4-tetrazolil-4-fenilpiperidina para tratar el dolor
ES2136673T3 (es) Utilizacion del factor de crecimiento de los queratinocitos para la obtencion de medicamentos.
BR9507730A (pt) Uso de formulações em gel como composições de tratamento
ES2149759T3 (es) Vacuna contra la enfermedad de lyme.
AR027688A1 (es) Acilsulfimidas heterociclicas, procedimiento para su preparacion, agentes que las contienen y su empleo como agentes para combatir animales perjudiciales
ATE368227T1 (de) Screening nach verbindungen, die tgf-beta abhängige zellsignale modifizieren können
AR038853A1 (es) Una composicion parasiticida inyectable
HU9201197D0 (en) Protection from shock subsequent to injury by double-stranded rns
UY26498A1 (es) Pirroles sustituidos
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.
AR007952A1 (es) Procedimiento para el tratamiento antiparasitario de sitios infestados o capaces de ser infestados por escarabajos oscuros y las camas para animales y/o suelos o estiercol tratados con dicho procedimiento.
ATE245604T1 (de) Verwendung von porphyrinderivaten in aquarien
ES2153584T3 (es) Piridiniminil-1,2-benzisoxazol y -benzisotiazol como antipsicoticos.
ES2132283T3 (es) Derivados n-heteroaril sustituidos de propanamida utiles en el tratamiento de enfermedades cardiovasculares.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 579791

Country of ref document: ES